Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Debt (2016 - 2025)

Abeona Therapeutics has reported Total Debt over the past 11 years, most recently at $20.0 million for Q4 2025.

  • Quarterly results put Total Debt at $20.0 million for Q4 2025, up 5.65% from a year ago — trailing twelve months through Dec 2025 was $20.0 million (up 5.65% YoY), and the annual figure for FY2025 was $20.0 million, up 5.65%.
  • Total Debt for Q4 2025 was $20.0 million at Abeona Therapeutics, up from $19.8 million in the prior quarter.
  • Over the last five years, Total Debt for ABEO hit a ceiling of $28.4 million in Q3 2021 and a floor of $1.8 million in Q1 2021.
  • Median Total Debt over the past 4 years was $18.2 million (2024), compared with a mean of $14.0 million.
  • Peak annual rise in Total Debt hit 1513.2% in 2021, while the deepest fall reached 93.72% in 2021.
  • Abeona Therapeutics' Total Debt stood at $8.4 million in 2021, then tumbled by 50.6% to $4.2 million in 2022, then soared by 355.51% to $19.0 million in 2024, then increased by 5.65% to $20.0 million in 2025.
  • The last three reported values for Total Debt were $20.0 million (Q4 2025), $19.8 million (Q3 2025), and $19.6 million (Q2 2025) per Business Quant data.